Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy
Articolo
Data di Pubblicazione:
2021
Abstract:
Krebs von den Lungen-6 (KL-6) was suggested as ILD biomarker including idiopathic pulmonary fibrosis (IPF). Lung cancer is one of the most severe comorbidity of IPF patients. This study aims to serially analyze KL-6 in IPF patients after 24 months of Nintedanib and to first investigate the biomarker behavior in IPF associated with adenocarcinoma.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Krebs von den Lungen-6; antifibrotic therapies; idiopathic pulmonary fibrosis; lung cancer; pulmonary fibrosis associated with autoimmune diseases
Elenco autori:
D'Alessandro, Miriana; Bergantini, Laura; Cameli, Paolo; Pieroni, Maria; Refini, Rosa Metella; Sestini, Piersante; Bargagli, Elena
Link alla scheda completa:
Pubblicato in: